Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to Announce Quarterly Sales of $8.31 Million

Wall Street analysts expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) to report $8.31 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Alpine Immune Sciences’ earnings. The lowest sales estimate is $4.60 million and the highest is $15.33 million. Alpine Immune Sciences reported sales of $7.19 million during the same quarter last year, which indicates a positive year-over-year growth rate of 15.6%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Alpine Immune Sciences will report full-year sales of $65.98 million for the current fiscal year, with estimates ranging from $37.00 million to $102.00 million. For the next fiscal year, analysts forecast that the company will report sales of $40.07 million, with estimates ranging from $32.00 million to $45.90 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.

ALPN has been the topic of several research analyst reports. Zacks Investment Research cut Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Alpine Immune Sciences in a report on Tuesday, May 17th. Oppenheimer decreased their target price on Alpine Immune Sciences from $19.00 to $17.00 in a report on Monday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of Alpine Immune Sciences in a report on Friday, May 13th.

Institutional investors have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in Alpine Immune Sciences by 223.1% in the third quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 3,278 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Alpine Immune Sciences by 1.3% in the third quarter. Geode Capital Management LLC now owns 194,021 shares of the biotechnology company’s stock valued at $2,070,000 after acquiring an additional 2,483 shares during the last quarter. BlackRock Inc. boosted its holdings in Alpine Immune Sciences by 0.7% in the third quarter. BlackRock Inc. now owns 547,782 shares of the biotechnology company’s stock valued at $5,844,000 after acquiring an additional 3,627 shares during the last quarter. Two Sigma Investments LP lifted its stake in Alpine Immune Sciences by 131.9% in the third quarter. Two Sigma Investments LP now owns 39,218 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 22,304 shares during the period. Finally, Frazier Management LLC lifted its stake in Alpine Immune Sciences by 0.7% in the fourth quarter. Frazier Management LLC now owns 1,784,913 shares of the biotechnology company’s stock valued at $24,721,000 after buying an additional 13,069 shares during the period. Institutional investors and hedge funds own 77.00% of the company’s stock.

Shares of NASDAQ ALPN opened at $8.25 on Thursday. The firm’s 50-day simple moving average is $8.59 and its 200 day simple moving average is $9.83. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.02. The stock has a market cap of $250.22 million, a P/E ratio of -4.63 and a beta of 1.74. Alpine Immune Sciences has a fifty-two week low of $6.00 and a fifty-two week high of $14.40.

About Alpine Immune Sciences (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Featured Stories